Pfizer pneumococcal vaccine shows strong trial results
Pfizer's experimental vaccine showed higher antibody levels in infants than current shots. The company is now starting a late-stage trial for the new candidate.
Xurve View
Insights:
Xurve View
PFIZER INC reported its experimental 25-valent pneumococcal vaccine produced antibody levels 15 times higher than its current shot in a mid-stage trial. The 25vPnC candidate outperformed Prevnar 20 across all target strains in healthy infants. This advance matters because 25vPnC could protect against 90% of disease-causing strains in children under five, exceeding current immunizations.
